The field of schizophrenia: Strengths, weaknesses, opportunities, and threats

Schizophrenia Bulletin

Volumn 38, Issue 1, 2012, Pages 1-4

  Kane, John M ^a,b   Cornblatt, Barbara ^a,b   Correll, Christoph U ^a,b   Goldberg, Terry ^a,b   Lencz, Todd ^a,b   Malhotra, Anil K ^a,b   Robinson, Delbert ^a,b   Szeszko, Philip ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

course; diagnosis; diagnostic validity; outcome; treatment response

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO;

AWARENESS; CLINICAL EFFECTIVENESS; COGNITION; DRUG EFFICACY; EFFECT SIZE; EVIDENCE BASED PRACTICE; HUMAN; MENTAL DISEASE; MOTIVATION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RECURRENCE RISK; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SOCIAL INTERACTION; TREATMENT RESPONSE;

BIOMEDICAL RESEARCH; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84555188650     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbr131     Document Type: Review

References (33)

1. Angell M. "The Eepidemic of Mmental Iillness: Why?". The New York Review. New York, NY: The New York Review of Books; 2011.
2. Angell M. "The Illusions of Psychiatry". The New York Review. 2011.
3. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation drugs? A metaanalysis of placebo controlled trials. Mol Psychiatry. 2009;14:429-447.
4. Leucht S, Hierla S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication in perspective: A review of meta-analyses. Brit J Psychiatry. In Press.
5. Robinson D, Woerner M, Alvir J, et al. Predictors of relapse following response froma first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-247. (Pubitemid 29125132)
6. Velligan DI, Diamond P, Lopez J, et al. Cognition adaptation training improves adherence to medication and functional outcome in schizophrenia. Schizophr Bull. 2007;33:608.
7. Tiihonen J, Walhbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333:224.
8. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603-609.
9. Kane JM. Novel method to monitor medication adherence and physiologic parameters in psychiatric patients using ingestible markers: early clinical experience. Presented at Annual NCDEU Meeting; 2011; Boca Raton, FL.
10. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev. 2010, (Issue 12). Art No.: CD000088 doi:10.1002/14651858CD000088.pub3.
11. NIMH. RAISE. http://nimh.nih.gov/health/topics/schizophrenia/raise/index. shtml. Accessed September 7, 2011.
12. Dickerson FB, Lehman AF. Evidence-based psychotherapy for schizophrenia: 2011 update. J Nerv Ment Dis. 2011; 199:520-526.
13. Dixon LB, Dickerson F, Bellack AS, et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull. 2010;36:48-70.
14. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36:71-93.
15. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, schizophrenia Patient Outcomes Research Team (PORT). The schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36:94-103.
16. Pantelis C, Velakoulis D, McGorry PD, et al. Neuroanatomical abnormalities before and after onset of psychosis: a crosssectional and longitudinal MRI comparison. Lancet. 2003; 361:281-288. (Pubitemid 36126187)
17. Borgwardt SJ, McGuire PK, Aston J, et al. Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. Br J Psychiatry. 2007;191:s69-s75. (Pubitemid 350273192)
18. Uhlhaas PJ, Singer W. The development of neural synchrony and large-scale cortical networks during adolescence: relevance for the pathophysiology of schizophrenia and neurodevelopmental hypothesis. Schizophr Bull. 2011;37:514-523.
19. Bilder RM, Reiter G, Bates J, et al. Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol. 2006;28:270-282. (Pubitemid 43254519)
20. Mittal VA, Neumann C, Saczawa M, Walker EF. Longitudinal progression of movement abnormalities in relation to psychotic symptoms in adolescents at high risk of schizophrenia. Arch Gen Psychiatry. 2008;65:165-171. (Pubitemid 351214315)
21. Walker E, Emory E. Infants at risk for psychopathology: offspring of schizophrenic parents. Child Dev. 1983;54: 1269-1285.
22. Correll CU, Hauser M, Auther AM, Cornblatt BA. Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry. 2010;51:390-431.
23. Carpenter WT, van Os J. Should attenuated psychosis syndrome be a DSM-5 diagnosis? Am J Psychiatry. 2011;168: 460-463.
24. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167:748-751.
25. Cuthbert BN, Insel TR. Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria project. Schizophr Bull. 2010;36:1061-1062.
26. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies. Am J Psychiatry. 2004;161:414-425. (Pubitemid 38326094)
27. Koning JP, Tenback DE, van Os J, Aleman A, Kahn RS, van Harten PN. Dyskinesia and parkinsonism in antipsychoticnaive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis. Schizophr Bull. 2010; 36:723-731.
28. Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry. 1995;152:1724-1729.
29. Fenton WS, Blyler CR, Wyatt RJ, McGlashan TH. Prevalence of spontaneous dyskinesia in schizophrenic and nonschizophrenic psychiatric patients. Br J Psychiatry. 1997;171:265-268. [Erratum appears in Br J Psychiatry 1998 Jan;172:97]. (Pubitemid 27400303)
30. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17:97-107.
31. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011;68:128-137.
32. Malla AK, Bodnar M, Joober R, Lepage M. Duration of untreated psychosis is associated with orbital-frontal grey matter volume reductions in first episode psychosis. Schizophr Res. 2011;125:13-20.
33. Van Haren NEM, Hulshoff Pol HE, Schnack HG, et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5 year follow-up study. Neuropsychopharmacology. 2007;32:2057-2066. (Pubitemid 47417696)